Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug maker focused on chemical prescription medicines, operates under China’s pharmaceutical regulatory regime and maintains listings in both mainland China and Hong Kong. The company’s governance structure includes executive, non-executive and independent non-executive directors, reflecting a typical listed-pharma board setup.
The company has obtained a Drug Registration Certificate from the National Medical Products Administration for its 0.2g Entacapone Tablets, classified as a Class 4 chemical prescription drug for domestic production. This approval, following an application accepted by the Center for Drug Evaluation in October 2024, enables Xinhua Pharmaceutical to move toward compliant manufacturing and sales of the product, potentially strengthening its product portfolio and commercial position in China’s prescription drug market.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based drug manufacturer listed in Hong Kong, operating in the pharmaceutical industry with a focus on chemical prescription medicines. The company develops and produces domestically marketed drugs, positioning itself within China’s regulated medical products sector under the National Medical Products Administration framework.
Average Trading Volume: 1,133,891
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.16B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.